Ricoh Biosciences is a leading innovator in human induced pluripotent stem cell (iPSC) technology, delivering high-fidelity human cell models and next-generation regenerative medicine solutions. Through strategic co-development, we partner with biopharmaceutical companies to create custom iPSC-derived cell types including complex neurons, glial populations, immune cells, and emerging regenerative medicine applications. We also co-develop disease-relevant models, advanced screening platforms, and early therapeutic candidates, leveraging our transcriptome-guided differentiation approach to generate cells that faithfully recapitulate human biology with exceptional precision and reproducibility. Our regenerative medicine pipeline includes an allogeneic iPSC-derived dopaminergic neuron engineered for stability, maturity, and strong translational potential, representing a promising candidate for neurodegenerative disease applications.